🔥🐔 BizChicken 🐔🔥
Companies Similar to 4D Molecular Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Alector, Inc.
AL001, AL101, AL002, AL003, AL044
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.
About | Vision/Values | History | Leadership | Contact | Culture | Vision/Values | History | About | About | About | About | Careers | About | About
Symbol: ALEC
Recent Price: $1.72
Industry: Biotechnology
CEO: Dr. Arnon Rosenthal Ph.D.
Sector: Healthcare
Employees: 245
Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 415 231 5660
Leadership
- Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
- Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
- Marc Grasso, M.D., Chief Financial Officer
- Gary Romano, M.D., Ph.D., Chief Medical Officer
- Danielle Pasqualone, Ph.D., J.D., General Counsel
- Clare Hunt, M.B.A., Chief People Officer
- Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
- Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
- Norah Conway, Senior Vice President, Portfolio and Program Management
- Neil Berkley, M.S., M.B.A., Chief Business Officer
- Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
- Elizabeth Garofalo, M.D., Board Member
- Paula Hammond, Ph.D., Board Member
- Richard H. Scheller, Ph.D., Board Member
- David Wehner, Board Member
- Kristine Yaffe, M.D., Board Member
- Errol De Souza, Ph.D., Board Member
- Mark Altmeyer, M.B.A., Board Member
Last updated: 2024-12-31
Applied Therapeutics, Inc.
AT-007
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.
About | Leadership | Leadership | Leadership | Leadership | Vision/Values | Culture | DEI | Contact | Contact | Careers | Careers | About | About | About
Symbol: APLT
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Shoshana Shendelman Ph.D.
Sector: Healthcare
Employees: 31
Address: 545 Fifth Avenue, New York, NY 10017
Phone: 212 220 9226
Leadership
- Shoshana Shendelman, Chair, Board of Directors
- Riccardo Perfetti, Chief Medical Officer
- Les Funtleyder,
- Dale Hooks, Chief Commercial Officer
- Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
- Joel Marcus,
- Jay Skyler,
- Stacy Kanter,
- Teena Lerner,
- Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
- Roy Freeman M.D.,
- Roxana Mehran M.D.,
- Lawrence Steinman M.D.,
- Gregg Stone M.D.,
- Donald d'Amico M.D.,
- Donald Landry, Chair, Scientific Advisory Board
- Roy Freeman,
- Roxana Mehran,
- Lawrence Steinman,
- Gregg Stone,
- Donald d'Amico,
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Voyager Therapeutics, Inc.
VY-AADC
Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.
About | Vision/Values | Leadership | Vision/Values | Careers | Benefits | Careers | Careers | About | About | Careers | Culture | About
Symbol: VYGR
Recent Price: $5.59
Industry: Biotechnology
CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Sector: Healthcare
Employees: 162
Address: 75 Sidney Street, Cambridge, MA 02139
Phone: 857 259 5340
Leadership
- Alfred Sandrock, M.D., Ph.D.,
- Todd Carter, Ph.D., Chief Scientific Officer
- Jacquelyn Fahey Sandell, Chief Legal Officer
- Toby Ferguson, M.D., Ph.D., Chief Medical Officer
- Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
- Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
- Michelle Quinn Smith, Chief Human Resources Officer
- Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
- Michael Higgins, Chair
- Grace E. Colón, Ph.D.,
- James Geraghty,
- Steven Hyman, M.D,
- Catherine J. Mackey, Ph.D.,
- Jude Onyia, Ph.D.,
- Glenn Pierce, M.D., Ph.D.,
- George Scangos, Ph.D.,
- Nancy Vitale,
- Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
- Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
- Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.
Last updated: 2024-12-31
Tenaya Therapeutics, Inc.
TN-201, TN-301, TN-401
Tenaya Therapeutics, Inc. is a biotechnology company that discovers, develops, and delivers therapies for heart disease using cellular regeneration, gene therapy, and precision medicine platforms.
Symbol: TNYA
Recent Price: $1.45
Industry: Biotechnology
CEO: Mr. Faraz Ali M.B.A.
Sector: Healthcare
Employees: 140
Address: 171 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 825 6900
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
Adicet Bio, Inc.
ADI-001
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.
Symbol: ACET
Recent Price: $0.90
Industry: Biotechnology
CEO: Mr. Chen Schor BA, CPA, M.B.A.
Sector: Healthcare
Employees: 143
Address: 200 Clarendon Street, Boston, MA 02116
Phone: 650 503 9095
Last updated: 2024-12-31
Adial Pharmaceuticals, Inc.
AD04
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders. Its lead product, AD04, is in Phase III clinical trial for alcohol use disorder treatment.
Symbol: ADIL
Recent Price: $1.03
Industry: Biotechnology
CEO: Mr. Cary John Claiborne MBA
Sector: Healthcare
Employees: 4
Address: 1180 Seminole Trail, Charlottesville, VA 22901
Phone: 434 422 9800
Last updated: 2024-12-31
Adverum Biotechnologies, Inc.
ADVM-022
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing gene therapy product candidates for the treatment of ocular and rare diseases. Their lead product, ADVM-022, targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema.
Symbol: ADVM
Recent Price: $4.69
Industry: Biotechnology
CEO: Dr. Laurent Fischer
Sector: Healthcare
Employees: 121
Address: 800 Saginaw Drive, Redwood City, CA 94063
Phone: 650 656 9323
Last updated: 2024-12-31
Avalo Therapeutics, Inc.
AVTX-002, AVTX-007, AVTX-801
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.
Symbol: AVTX
Recent Price: $7.80
Industry: Biotechnology
CEO: Dr. Garry A. Neil M.D.
Sector: Healthcare
Employees: 19
Address: 540 Gaither Road, Rockville, MD 20850
Phone: 410 522 8707
Leadership
- Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
- Mittie Doyle, MD, FACR, Chief Medical Officer
- Chris Sullivan, Chief Financial Officer
- Paul Varki, Chief Legal Officer
- Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
- Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
- Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
- June Almenoff, MD, PhD, President and Chief Medical Officer
- Mitchell Chan, Chief Financial Officer
- Jonathan Goldman, MD, CEO
- Aaron Kantoff, Managing Partner
- Gilla Kaplan, PhD, Independent Director
- Samantha Truex, CEO
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
C4 Therapeutics, Inc.
CFT7455
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Their lead product candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas.
Symbol: CCCC
Recent Price: $3.64
Industry: Biotechnology
CEO: Mr. Andrew J. Hirsch M.B.A.
Sector: Healthcare
Employees: 145
Address: 490 Arsenal Way, Watertown, MA 02472
Phone: 617 231 0700
Leadership
- Kendra Adams, Chief Financial Officer
- Scott Boyle, Ph.D., Chief Business Officer
- Stew Fisher, Ph.D., Chief Scientific Officer
- Len Reyno, M.D., Chief Medical Officer
- Jolie Siegel, Chief Legal Officer
- Kelly Schick, Chief People Officer
- Mary Christian, Pharm. D., Senior Vice President, Regulatory
- Mayra Reyes-Armour, Ph.D., Senior Vice President, Technical Operations, Quality and Facilities
- Ron Cooper, Chairman
- Ken Anderson, M.D., Director
- Laura Bessen, M.D., Director
- Bruce Downey, Director
- Stephen Fawell, Ph.D., Director
- Donna Grogan, M.D., Director
- Andrew Hirsch, President and Chief Executive Officer, Director
- Owen Hughes, Director
- Utpal Koppikar, Director
- Marc Cohen, In MemoriamCo-Founder & Executive Chairman Emeritus
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Indaptus Therapeutics, Inc.
Decoy20
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.
Symbol: INDP
Recent Price: $0.87
Industry: Biotechnology
CEO: Mr. Jeffrey A. Meckler
Sector: Healthcare
Employees: 7
Address: 3 Columbus Circle, New York, NY 10019
Phone: 347 480 9760
Last updated: 2024-12-31
Vir Biotechnology, Inc.
Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111
Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.
Vision/Values | About | Leadership | About | Contact | Contact | Careers | Jobs | About | About
Symbol: VIR
Recent Price: $7.33
Industry: Biotechnology
CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Sector: Healthcare
Employees: 587
Address: 499 Illinois Street, San Francisco, CA 94158
Phone: 415 906 4324
Leadership
- Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
- Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
- Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
- Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
- Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
- Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
- Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
- Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
- Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
- Arran Attridge, Senior Vice President Corporate Communications
- Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
- Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
MeiraGTx Holdings plc
Gene Therapy Treatments
Meira GTx Holdings plc is a clinical stage gene therapy company developing treatments for serious diseases, including ocular diseases, xerostomia, and neurodegenerative conditions. They are in various stages of clinical development for several gene therapy programs and have a research collaboration with Janssen Pharmaceuticals.
About | Leadership | About | Contact | About | About | About | News | About | About | About | Directors
Symbol: MGTX
Recent Price: $5.89
Industry: Biotechnology
CEO: Dr. Alexandria Forbes Ph.D.
Sector: Healthcare
Employees: 387
Address: 430 East 29th Street, New York, NY 10016
Phone: 646 860 7985
Leadership
- Alexandria Forbes, Ph.D., Board Member, President and Chief Executive Officer
- Richard Giroux, Chief Operating Officer and Chief Financial Officer
- Stuart Naylor, Ph.D., Chief Development Officer
- Robert K. Zeldin, M.D., Chief Medical Officer
- Robert Wollin, JD, General Counsel and Secretary
- Alastair Leighton, Ph.D, SVP, Manufacturing and Supply Chain
- Christine Sheehy, SVP, Global Integration
- Tim Randall, SVP, Risk and Internal Controls
- Michel Michaelides, M.D., Head of Clinical Ophthalmology
- Tassos Georgiadis, Ph.D., Vice President, Preclinical Development
- Keith R. Harris, Ph.D., Chairman of the Board
- Ellen Hukkelhoven, Ph.D., Board Member
- Lord Mendoza, Independent Board Member
- Nicole Seligman, Independent Board Member
- Thomas E. Shenk, Ph.D., Independent Board Member
- Debra Yu, M.D., Independent Board Member
Last updated: 2024-12-31
Stoke Therapeutics, Inc.
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31